Breast-specific gamma scans monitor chemo
Breast-specific gamma imaging is highly accurate in monitoring the response of breast cancers to neoadjuvant chemotherapy, according to a study presented at the American Society of Breast Surgeons' annual meeting in Las Vegas.
Breast-specific gamma imaging is highly accurate in monitoring the response of breast cancers to neoadjuvant chemotherapy, according to a study presented at the American Society of Breast Surgeons' annual meeting in Las Vegas.
In their 12-subject study, George Washington University Hospital researchers found gamma imaging accurately establishes tumor size within 5 mm after neoadjuvant chemotherapy. The pathologic size ranged from 2.6 cm to 2 mm postchemotherapy. In addition, the correlation coefficients are superior to those of other modalities, including physical exam, mammography, ultrasound, MRI, and FDG-PET, according to the authors.
The researchers compared gamma camera breast tumor images postchemotherapy with pathologic size at excision. They found the gamma imaging accurately reflected tumor size in all 12 patients.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
